Yüklüyor......
A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors
PURPOSE: Bevacizumab is an antibody against vascular endothelial growth factor (VEGF); sunitinib is an inhibitor of VEGF and related receptors. The safety and maximum tolerated dose (MTD) of sunitinib plus bevacizumab was assessed in this phase I trial. EXPERIMENTAL DESIGN: Patients with advanced so...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2009
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2756318/ https://ncbi.nlm.nih.gov/pubmed/19773375 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-09-0717 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|